**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington      D.C. 20549**

| (Mark                One)                                                                                                                                                                                                                                                                             |                                                                                                            |            **FORM 10-QSB** |           |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------|--------|
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| [X]                                                                                                                                                                                                                                                                                                   | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934 |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| **For                the quarterly period ended June 30, 2007**                                                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| [   ]                                                                                                                                                                                                                                                                                  | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT                                  |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| For                the transition period from ________________ to                ________________                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| 000-51561                                                                                                                                                                                                                                                                                             |
| (Commission                file number)                                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| **HEALTHCARE                PROVIDERS DIRECT, INC.**                                                                                                                                                                                                                                                  |
| (Exact                name of small business issuer as specified in its                charter)                                                                                                                                                                                                       |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            | **Nevada**                                                                        | **20-1063591** |   |   |
|                                     (State                or other jurisdiction of incorporation or organization) |                                                                                                            |  (IRS                Employer Identification No.)                            |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| **3371****Route                One, Suite 200**                                                                                                                                                                                                                                                       |
| **Lawrenceville,                New Jersey 08648**                                                                                                                                                                                                                                                    |
| (Address                of principal executive offices)                                                                                                                                                                                                                                               |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| (609)                919-1932                                                                                                                                                                                                                                                                         |
| (Issuer’s                telephone number)                                                                                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| **N/A**                                                                                                                                                                                                                                                                                               |
| (Former                name, former address and former fiscal year, if changed since last                report)                                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| Check                whether the issuer (1) filed all reports required to be filed by                Section                13 or 15(d) of the Exchange Act during the past 12 months (or for                such                shorter period that the registrant was                               |
| Required                to file such reports and (2) has been subject to such filing requirements                for the past 90 days.  Yes [X] No                [  ]                                                                                                            |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| State                the number of shares outstanding of each of the issuer’s classes of common                equity, as of the latest practicable date: As of August 10, 2007–                44,864,038 shares of common stock                                                         |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| Indicate                by check mark whether the registrant is a shell company (as defined                in                Rule 12b-2 of the Exchange Act). Yes [  ] No                [X]                                                                                                |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
|                                                                                                                                                                                                                                                                                                  |                                                                                                            |                                                                              |           |   |
| Transitional                Small Business Disclosure Format (check one): Yes [  ] No                [X]                                                                                                                                                                                    |

----

**HEALTHCARE      PROVIDERS DIRECT, INC.**

**Index**

|                   |                                                                                                                                                  | Page Number |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
|                   |                                                                                                                                                  |             |
| PART                I. | FINANCIAL                INFORMATION                                                                                                                  | 3                |
|                   |                                                                                                                                                  |             |
| Item                1. | Financial                Statements                                                                                                                   | 3                |
|                   |                                                                                                                                                  |             |
|                   | Condensed                Balance Sheet as of June 30, 2007 (unaudited)                                                                                | 3                |
|                   |                                                                                                                                                  |             |
|                   | Condensed                Statements of Operations for the three and six months ended June                30, 2007                and 2006 (unaudited) | 4                |
|                   |                                                                                                                                                  |             |
|                   | Condensed                Statement of Stockholders (Deficiency) for the six months ended June                30,                2007 (unaudited)      | 5                |
|                   |                                                                                                                                                  |             |
|                   | Condensed                Statements of Cash Flows for the six months ended June 30, 2007 and                2006                (unaudited)           | 6                |
|                   |                                                                                                                                                  |             |
|                   | Notes                to the Condensed Financial Statements                                                                                            | 7                |
|                   |                                                                                                                                                  |             |
| Item                2. | Management’s                Discussion and Analysis of Plan of Operations                                                                       | 15               |
|                   |                                                                                                                                                  |             |
| Item                3. | Controls                and Procedures                                                                                                                | 21               |
|                   |                                                                                                                                                  |             |
| PART                II | OTHER                INFORMATION                                                                                                                      | 22               |
|                   |                                                                                                                                                  |             |
| Item                1. | Legal                Proceedings                                                                                                                      | 22               |
|                   |                                                                                                                                                  |             |
| Item                2. | Unregistered                Sales of Equity Securities and  Use of Proceeds                                                                 | 22               |
|                   |                                                                                                                                                  |             |
| Item                3. | Defaults                Upon Senior Securities                                                                                                        | 22               |
|                   |                                                                                                                                                  |             |
| Item                4. | Submission                of Matters to a Vote of Security Holders                                                                                    | 22               |
|                   |                                                                                                                                                  |             |
| Item                5. | Other                Information                                                                                                                      | 22               |
|                   |                                                                                                                                                  |             |
| Item                6. | Exhibits                                                                                                                                              | 22               |
|                   |                                                                                                                                                  |             |
| SIGNATURES             | 23                                                                                                                                                    |

----

|                                                                                                                                                              |   | June                30, 2007(unaudited) |       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------|------------|
| ASSETS                                                                                                                                                            |   |                                    |       |
| Current                Assets:                                                                                                                                    |   |                                    |       |
|      Cash                and cash equivalents                                                                                            |   | $                                       | 10,891     |   |
|      Accounts                receivable, net of allowance for doubtful accounts, of                $33,345                               |   |                                    | 51,226     |   |
|      Inventories                                                                                                                         |   |                                    | 107,877    |   |
|      Prepaid                and other current assets                                                                                     |   |                                    | 83,118     |   |
|           Total                current assets                                                                   |   |                                    | 253,112    |   |
|                                                                                                                                                              |   |                                    |       |   |
| Equipment,                net of accumulated depreciation of $15,755                                                                                              |   |                                    | 21,776     |   |
| Intangible                assets, net of amortization of $125,000                                                                                                 |   |                                    | 125,000    |   |
|           Total                assets                                                                           |   | $                                       | 399,888    |   |
|                                                                                                                                                              |   |                                    |       |   |
|                                                                                                                                                              |   |                                    |       |   |
| LIABILITIES                AND STOCKHOLDERS EQUITY                                                                                                                |   |                                    |       |   |
| Current                liabilities:                                                                                                                               |   |                                    |       |   |
| Accounts                payable                                                                                                                                   |   | $                                       | 392,163    |   |
| Accrued                expenses and other current liabilities                                                                                                     |   |                                    | 393,545    |   |
| Accrued                royalties                                                                                                                                  |   |                                    | 119,195    |   |
| Notes                payable                                                                                                                                      |   |                                    | 90,000     |   |
|           Total                current liabilities                                                              |   |                                    | 994,903    |   |
|                                                                                                                                                              |   |                                    |       |   |
| Commitments                and contingencies                                                                                                                      |   |                                    | -          |   |
|                                                                                                                                                              |   |                                    |       |   |
| Stockholders’                deficiency                                                                                                                     |   |                                    |       |   |
|      Common                stock,  $.001 par  value;                                                                 |   |                                    |       |   |
|           375,000,000                shares authorized; 44,864,038 shares issued and                outstanding |   |                                    | 44,864     |   |
|      Additional                paid-in capital                                                                                           |   |                                    | 6,270,264  |   |
|      Accumulated                deficit                                                                                                  |   |                                    | (6,910,143 | ) |
|           Total                stockholders’ deficiency                                                   |   |                                    | (595,015   | ) |
|           Total                liabilities and stockholders’ deficiency                                   |   | $                                       | 399,888    |   |

----

|                                                                  |   | For                The Three Months Ended |       |   | For                The Six Months Ended |   |
|-----------------------------------------------------------------------|--------|-------------------------------------------|------------|--------|----------------------------------------------|--------|
|                                                                  |   | June                30, 2007              |       |   | June30,2006                                  |   |   | June                30, 2007 |   |   | June30,2006 |   |
| Revenues,                net                                          |   | $                                         | 168,672    |   |                                         | $      | 113,494 |   |   | $ | 307,570 |   |   | $ | 281,988 |   |
| Cost                of revenues                                       |   |                                      | 85,651     |   |                                         |   | 62,228 |   |   |   | 147,472 |   |   |   | 135,273 |   |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Gross                profit                                           |   |                                      | 83,021     |   |                                         |   | 51,266 |   |   |   | 160,098 |   |   |   | 146,715 |   |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Operating                expenses:                                    |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Research  and                development                    |   |                                      | 160,406    |   |                                         |   | 10,993 |   |   |   | 207,688 |   |   |   | 28,733 |   |
| Marketing                and selling                                  |   |                                      | 257,246    |   |                                         |   | 106,630 |   |   |   | 485,363 |   |   |   | 187,305 |   |
| Issuance                of warrants in connection with reverse merger |   |                                      | -          |   |                                         |   | - |   |   |   | 2,927,285 |   |   |   | - |   |
| General                and administrative                             |   |                                      | 478,191    |   |                                         |   | 265,992 |   |   |   | 1,331,947 |   |   |   | 494,755 |   |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Total                operating expenses                               |   |                                      | 895,843    |   |                                         |   | 383,615 |   |   |   | 4,952,283 |   |   |   | 710,793 |   |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Loss                from operations                                   |   |                                      | (812,822   | )      |                                         |   | (332,349 | ) |   |   | (4,792,185 | ) |   |   | (564,078 | ) |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Other                income and expense:                              |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
|      Interest                income          |   |                                      | 843        |   |                                         |   | 19 |   |   |   | 2,309 |   |   |   | 158 |   |
|      Interest                expense         |   |                                      | (2,857     | )      |                                         |   | (5,143 | ) |   |   | (7,263 | ) |   |   | (6,854 | ) |
| Other                income, net                                      |   |                                      | (2,014     | )      |                                         |   | (5,124 | ) |   |   | (4,954 | ) |   |   | (6,696 | ) |
| Net                loss                                               |   | $                                         | (814,836   | )      |                                         | $      | (337,473 | ) |   | $ | (4,797,139 | ) |   | $ | (570,774 | ) |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Cumulative                dividends on Preferred Stock                |   |                                      | -          |   |                                         |   | (8,026 | ) |   |   | - |   |   |   | (28,802 | ) |
| Net                loss applicable to Common Shareholders             |   | $                                         | (814,836   | )      |                                         | $      | (345,499 | ) |   | $ | (4,797,139 | ) |   | $ | (599,576 | ) |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |
| Net                Loss Per Common Share -Basic and Diluted           |   | $                                         | (0.018     | )      |                                         | $      | (0.017 | ) |   | $ | (0.107 | ) |   | $ | (0.030 | ) |
| Weighted                average common shares - Basic and Diluted     |   |                                      | 44,864,038 |   |                                         |   | 19,929,236 |   |   |   | 44,864,038 |   |   |   | 19,929,236 |   |
|                                                                  |   |                                      |       |   |                                         |   |   |   |   |   |   |   |   |   |   |   |

----

|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   | **Additional**          |   |   |      |   |      |             |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-----------------------------------------|--------|--------|---------------------------------|--------|------------|-------------|--------|--------|--------------|--------|--------|-------------------------|--------|--------|-----------|--------|-----------|------------------|--------|
|                                                                                                                                                                                                                                                                   |   | **Series                B Convertible** |   |   |                            |   |       |        |   |   | **Paid-In-** |   |   | **Accumulated**         |   |   | **Total** |   |
|                                                                                                                                                                                                                                                                   |   | **Preferred                Stock (1)**  |   |   | **Common                Stock** |   |       | **Capital** |   |   | **Deficit**  |   |   | **Stockholders’** |   |
|                                                                                                                                                                                                                                                                   |   | **Shares**                              |   |   | **Amount**                      |   |       | **Shares**  |   |   | **Amount**   |   |   |                    |   |   |      |   |      | **(Deficiency)** |   |
| Balance                as of December 31, 2006                                                                                                                                                                                                                         |   |                                    | -      |   |                            | $      | -          |        |   |   | 34,874,749   |   |   | $                       | 34,875 |   |      | $      | 1,337,981 |             |   | $ | (2,113,004 | ) |   | $ | (740,148 | ) |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
| Issuance                of Series B Preferred  Stock                                                                                                                                                                                                         |   |                                    | 1,303  |   |                            |   | 1,144,153  |        |   |   | -            |   |   |                    | -      |   |      |   | -         |             |   |   | - |   |   |   | 1,144,153 |   |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
| Series                B Preferred Stock Conversion                                                                                                                                                                                                                     |   |                                    | (1,303 | )      |                            |   | (1,144,153 | )           |   |   | 9,589,289    |   |   |                    | 9,589  |   |      |   | 1,134,564 |             |   |   | - |   |   |   | - |   |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
| Issuance                of common                                                                                                                                                                                                                                      |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
| stock                                                                                                                                                                                                                                                                  |   |                                    | -      |   |                            |   | -          |        |   |   | 400,000      |   |   |                    | 400    |   |      |   | 499,600   |             |   |   | - |   |   |   | 500,000 |   |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
| Stock                based                                                                                                                                                                                                                                             |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
| compensation                expense                                                                                                                                                                                                                                    |   |                                    | -      |   |                            |   | -          |        |   |   | -            |   |   |                    | -      |   |      |   | 343,678   |             |   |   | - |   |   |   | 343,678 |   |
| Warrants                issued to                                                                                                                                                                                                                                      |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
|  board                members                                                                                                                                                                                                                                     |   |                                    | -      |   |                            |   | -          |        |   |   | -            |   |   |                    | -      |   |      |   | 27,156    |             |   |   | - |   |   |   | 27,156 |   |
| Issuance                of warrants in connection with reverse merger                                                                                                                                                                                                  |   |                                    | -      |   |                            |   | -          |        |   |   | -            |   |   |                    | -      |   |      |   | 2,927,285 |             |   |   | - |   |   |   | 2,927,285 |   |
| Net                Loss for the six months ended June 30, 2007                                                                                                                                                                                                         |   |                                    | -      |   |                            |   | -          |        |   |   | -            |   |   |                    | -      |   |      |   | -         |             |   |   | (4,797,139 | ) |   |   | (4,797,139 | ) |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
| Balances                as of June 30, 2007                                                                                                                                                                                                                            |   |                                    | -      |   |                            | $      | -          |        |   |   | 44,864,038   |   |   | $                       | 44,864 |   |      | $      | 6,270,264 |             |   | $ | (6,910,143 | ) |   | $ | (595,015 | ) |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
|                                                                                                                                                                                                                                                                   |   |                                    |   |   |                            |   |       |        |   |   |         |   |   |                    |   |   |      |   |      |             |   |   |   |   |   |   |   |   |
|  (1)                See Note 1 of the Notes to the Condensed Financial Statements for                a                discussion of the Series A Preferred.                  |   |                                    |   |   |                            |   |       |        |   |   |         |

----

|                                                                                                                                                                  |   | **2007** |       |   | **2006** |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------|------------|--------|----------|--------|
|                                                                                                                                                                  |   |     |       |   |     |   |
| Cash                flows from operating activities:                                                                                                                  |   |     |       |   |     |   |
| Net                loss                                                                                                                                               |   | $        | (4,797,139 | )      |     | $      | (570,774 | ) |
| Adjustments                to reconcile net loss to net cash used in operating                activities:                                                             |   |     |       |   |     |   |   |   |
|      Depreciation                                                                                                                            |   |     | 5,152      |   |     |   | 2,351 |   |
|      Amortization                of intangible                                                                                               |   |     | 27,778     |   |     |   | 27,777 |   |
|      Stock-based                compensation expense                                                                                         |   |     | 343,678    |   |     |   | - |   |
|      Issuance                of warrants for services                                                                                        |   |     | 27,156     |   |     |   | - |   |
|      Issuance                of warrants in connection with reverse merger                                                                   |   |     | 2,927,285  |   |     |   | - |   |
|      Allowance                for doubtful accounts                                                                                          |   |     | (167       | )      |     |   | - |   |
|     Changes                in operating assets and liabilities:                                                                                   |   |     |       |   |     |   |   |   |
|      Accounts                receivable                                                                                                      |   |     | 9,101      |   |     |   | (5,585 | ) |
|      Inventories                                                                                                                             |   |     | 53,194     |   |     |   | (1,648 | ) |
|      Prepaid                expenses and other current assets                                                                                |   |     | (52,621    | )      |     |   | (32,901 | ) |
|      Accounts                payable                                                                                                         |   |     | 1,527      |   |     |   | 35,069 |   |
|      Accrued                expenses                                                                                                         |   |     | (179,113   | )      |     |   | 167,309 |   |
| Net                cash used in operating activities                                                                                                                  |   |     | (1,634,169 | )      |     |   | (378,402 | ) |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
| Cash                flows from investing activities:                                                                                                                  |   |     |       |   |     |   |   |   |
| Purchases                of office & computer equipment:                                                                                                          |   |     | (12,587    | )      |     |   | (2,348 | ) |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
| Cash                flows from financing activities:                                                                                                                  |   |     |       |   |     |   |   |   |
|      Proceeds                from notes payable                                                                                              |   |     |       |   |     |   | 240,000 |   |
|      Payment                of notes payable                                                                                                 |   |     | (250,000   | )      |     |   | - |   |
|      Proceeds                from issuance of common stock                                                                                   |   |     | 500,000    |   |     |   | - |   |
|      Proceeds                from sale of Series B preferred stock, net of issuance costs of $158,847                and $2,493 respectively |   |     | 1,144,153  |   |     |   | 72,507 |   |
| Net                cash provided by financing activities                                                                                                              |   |     | 1,394,153  |   |     |   | 312,507 |   |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
| Net  (decrease)                in cash and cash equivalents                                                                                                 |   |     | (252,603   | )      |     |   | (68,243 | ) |
| Cash                and cash equivalents at beginning of period                                                                                                       |   |     | 263,494    |   |     |   | 122,976 |   |
| Cash                and cash equivalents at end of period                                                                                                             |   | $        | 10,891     |   |     | $      | 54,733 |   |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
| Supplemental                disclosures of cash flow information:                                                                                                     |   |     |       |   |     |   |   |   |
| Cash                paid during period for interest                                                                                                                   |   | $        | 19,230     |   |     | $      | 654 |   |
| Cash                paid during period for taxes                                                                                                                      |   |     | 1,830      |   |     |   | 750 |   |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
| Supplemental                Non-Cash Financing Transactions:                                                                                                          |   |     |       |   |     |   |   |   |
|      Conversion                of note payable into Series A redeemable preferred stock                (1)                                   |   |     | -          |   |     | $      | 25,000 |   |
|      Conversion                of Series B preferred stock into common                                                                       |   |     | 2,548,000  |   |     |   | - |   |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |
| (1)                See Note 1 of the Notes to the Condensed Financial Statements for                a                discussion of the Series A Preferred.            |   |     |       |   |     |   |   |   |
|                                                                                                                                                                  |   |     |       |   |     |   |   |   |

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

**I.       BASIS      OF PRESENTATION**

|   | ***Basis                of Presentation*****—**Healthcare Providers                Direct, Inc (the “Company”) was incorporated in the state of Delaware on                October 29, 2004 and commenced operations on January3,                2005. The Company, located in Lawrenceville, New Jersey, sells and                distributes diagnostic tests directly to physician offices and other                healthcare providers in the United States. During the six months                ended                June 30, 2007, the Company completed a share exchange with a public                Shell                Company (Reverse Merger) that was treated as a capital transaction,                which                requires equity to be restated to reflect the Merger and Share Exchange                as                of the earliest period presented. As a result, the Company’s Series A                Redeemable Convertible Preferred Stock, Series B Convertible Preferred                Stock and Common Stock have been reflected as Common Stock as of                the                earliest period-end presented.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | The                accompanying condensed financial statements included herein have                been  prepared  by the  Company  pursuant to the                rules and  regulations  of the Securities and                Exchange Commission  (the  "Commission")  for                interim  financial information.  Accordingly, they do not                include all of the information and footnotes required by accounting                principles generally accepted in the United States of America for                complete financial  statement  presentation and should be                read in conjunction with the audited  consolidated                 financial  statements and related footnotes  thereto for                the fiscal year ended December 31, 2006  included in the                 Company's  Current  Report on Form  8-K/A,                 filed  with the  Commission on May 8, 2007.                The financial  statements  presented  in this                 quarterly  report are  unaudited  but include all                adjustments  that are of a normal  recurring  nature that                management considers  necessary for the fair                 statement  of the  results  for the  interim                periods.  Results for interim periods are not                necessarily indicative of results for the full fiscal                year. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Effective                February 7, 2007, the Company entered into a definitive Share Exchange                Agreement with Alpha Motorsport, Inc., a Nevada corporation and the                shareholders of HPD pursuant to which HPD became a wholly-owned subsidiary                of the Company (the “Merger”). The share exchange agreement provided for                the acquisition of all of the issued and outstanding capital stock                of HPD                consisting of 4,683 shares of common stock (on an as-converted, issued                and                outstanding basis), in exchange for 34,464,038 shares of the Alpha                Motorsport’s common stock, par value $.001 per share (the “Share                Exchange”).   In connection with the Share Exchange                Agreeemnt, the Company assumed the obligation to register up to 400,000                shares of common stock issued by Alpha in a private placement (the“Alpha                Private Placement”).  In return, the Company received $500,000                upon the closing of the Merger on February 7, 2007.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|   | Prior                to the closing of the Share Exchange, the Company had 30,000,000                shares of                common stock issued and outstanding and subsequent to the Share Exchange                it had 44,864,038 shares of common stock issued and outstanding.                Upon the                closing of the Merger on February 7, 2007, HPD became a wholly-owned                subsidiary of the Company. The share exchange was accounted for as                a                reverse merger for accounting purposes. As a result, the Company                treated                the merger as a capital transaction and has retroactively revised                shareholders’ equity to give effect to the merger. Prior to the reverse                merger, each share of Series A and Series B preferred stock of HPD                was                automatically converted into one share of common stock. Effective                with the                reverse merger, all shares of common stock of HPD were exchanged                for                shares in the registrant, in accordance with the Share Exchange Agreement.                The following table shows the exchange of common stock in the reverse                merger:                                                                                                                                                                                                                                                                                                                                                                                         |

|                                    |   | Common                stock ofHPD                before shareExchange |   |   | Shares                of commonStock                in registrantafter                share exchange |   |
|-----------------------------------------|--------|-----------------------------------------------------------------------|--------|--------|------------------------------------------------------------------------------------------------------|--------|
| Series                A Preferred Stock |   |                                                                  | 577    |   |                                                                                                 |   | 4,246,370 |   |
| Series                B Preferred Stock |   |                                                                  | 2,548  |   |                                                                                                 |   | 18,751,734 |   |
| Common                stock             |   |                                                                  | 1,558  |   |                                                                                                 |   | 11,465,934 |   |
|      Total     |   |                                                                  | 4,683  |   |                                                                                                 |   | 34,464,038 |   |

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

|   | Upon                the closing of the Share Exchange, (i) 1,558 shares of common stock,                (ii)                577 shares of Series A Convertible Preferred Stock and (iii) 2,548                shares                of Series B ConvertiblePreferred                Stock of HPD were exchanged for 34,464,038 shares of common stock                of the                Alpha Motorsports.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | Sale                of Operating Subsidiary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | In                a related transaction, on February 7, 2007, pursuant to a Share Purchase                Agreement, Healthcare Providers Direct, Inc., a Nevada corporation                (f/ka                Alpha MotorSports, Inc.)sold                all of the outstanding stock of its British Columbia operating subsidiary,                Alpha Motorsport, Inc., to its former president for                $100,000.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | Investa                Warrants                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | On                February 7, 2007, the Company issued warrants to Investa Capital                Partners                Inc. (“Investa”) for services performed in connection with the reverse                merger transaction, which are exercisable in two tranches. The tranche                A                warrants give Investa the right to purchase 2,705,659 shares of common                stock at an exercise price of $0.1848 per share. The tranche B warrants                give Investa the right to purchase 2,032,982 shares of common stock                at an                exercise price of $0.2459 per share. The warrants had a fair value                of                $2,927,285 and have been recorded as an expense for the three months                ended                March 31, 2007.  Both the tranche A and the tranche B warrants are                exercisable for a period of 365 days from the date of issuance. Until                such                time that the Company has raised an aggregate of $2,500,000, the                Company                shall have the right to force Investa to exercise the tranche A and                the                tranche B Warrants in the following manner:                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | -  With                respect to the tranche A warrants, in the event the Company has not                raised                an aggregate of $2,500,000, the Company may force the exercise of                up to                $500,000 (2,705,659 shares) of the tranche A warrants no earlier                than 90                days from the date of issuance. - With                respect to the tranche B warrants, in the event the Company has not                raised                an aggregate of $2,500,000 and the Company has an effective registration                statement pursuant to the Securities Act covering all the shares                of common                stock underlying the tranche A warrant and the tranche B warrant,                the                Company may force the exercise of up to an $500,000 (2,032,982 shares)                of                the tranche B warrants no earlier than 90 days from the exercise                of                tranche A warrants.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | The                Company valued the put feature associated with these warrants and                determined that the value did not have a significant impact on the                financial statements for the six month period ended June 30,                2007.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | ***Liquidity*****—**The Company has net losses of ($4,797,139) for the six months                ended June 30, 2007, an accumulated deficit of ($6,910,143) and a                stockholders deficiency of ($595,015) as of June 30, 2007. In addition,                the Company has a net working capital deficiency of approximately                ($741,791) as of June 30, 2007. These circumstances raise substantial                doubt about the Company’s ability to continue as a going concern. The                Company has taken steps to mitigate the negative operating results                by                attempting to increase their sales by expanding their market, introduction                of new products, and an increased emphasis on sales and marketing.                The                Company’s ultimate success is dependent upon its ability to raise                additional capital. The Company completed a Share exchange into a                public                company shell on February 7, 2007, thereby offering access to the                public                markets (as mentioned above). The financial statements have been                prepared                on the basis that the Company is a going concern, which contemplates                the                realization of assets and the satisfaction of liabilities in the                normal                course of business. There have been no adjustments to the financial                statements to reflect the outcome of this                uncertainty. |

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

**2.       SUMMARY      OF SIGNIFICANT ACCOUNTING POLICIES**

|   | ***Uses                of Estimates*****—**The preparation of financial                statements in conformity with accounting principles generally accepted                in                the United States of America requires management to make estimates                and                assumptions that affect the reported amounts of assets and liabilities                and                disclosure of contingent assets and liabilities at the date of the                financial statements and the reported amounts of revenues and expenses                during the reporting period. Significant accounting estimates used                in the                Company’s financial statements included depreciation rates and allowances                for doubtful accounts. Actual results could differ from those                estimates.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | ***Income                Taxes*****—**The Company accounts for income tax                in accordance with Statement of Financial Accounting Standards (“SFAS”)                No. 109, *Accounting for Income Taxes*, which requires an asset and                liability approach to financial reporting for income taxes. Deferred                income tax assets and liabilities are computed for differences between                the                financial statement and tax bases of assets and liabilities that                will                result in taxable or deductible amounts in the future, based on enacted                tax laws and rates applicable to the periods in which the differences                are                expected to affect taxable income. Valuation allowances are established,                when necessary, to reduce the deferred tax assets to the amount expected                to be realized.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | ***Revenue                Recognition*****—**Revenue is recognized when                goods are shipped, provided that there is evidence of an arrangement                with                the customer, the price is fixed and determinable and collection                is                reasonably assured. The Company accrues for sales returns and other                allowances based upon specific customer situations and the Company's                history of sales returns.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | ***Share-Based                Compensation*****—**The Company accounts for its                stock options in accordance with SFAS No. 123(R), which requires                the                measurement and recognition of compensation expense for all share-based                payment awards based on estimated fair values at the date of the                grant.                Determining the fair value of share-based awards at the grant date                requires judgment in developing assumptions, which involve a number                of                variables. These variables include, but are not limited to, the expected                stock price volatility over the term of the awards, and expected                stock                option exercise behavior. In addition, we also use judgment in estimating                the number of share-based awards that are expected to be                forfeited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|   | ***Recent                Accounting Pronouncements*****—**In June, 2006                the FASB issued FASB Interpretation No. 48, Accounting for Uncertainty                in                Income Taxes, an interpretation of FASB Statement No. 109, Accounting                for                Income Taxes ("FIN 48"). FIN 48 clarifies the accounting for uncertainty                in income taxes recognized in a company's financial statements in                accordance with FASB Statement No. 109. FIN 48 stipulates a recognition                threshold and measurement attribute for the financial statement                recognition and measurement of a tax position taken or expected to                be                taken in a tax return. FIN 48 also provides guidance on derecognition,                classification, and interest and penalties. The provisions of FIN                48 are                to be effective for fiscal years beginning after December 15, 2006.                We                adopted FIN 48 on January 1, 2007. The adoption of FIN 48 did not                have a significant impact on our results of operations or financial                position. As a result of our continuing tax losses, we have historically                not paid income taxes and have recorded a full valuation allowance                against                our net deferred tax asset. Therefore, we have not recorded a liability                for unrecognized tax benefits prior to adoption of FIN 48 and there                was no                adjustment from the implementation. There continues to be no liability                related to unrecognized tax benefits at June 30, 2007. We recognize                interest and penalties related to unrecognized tax benefits in income                tax                expense. There was no accrued interest related to unrecognized tax                benefits at June 30, 2007. The tax years 2004-2006 remain open to                examination by the major taxing jurisdictions to which we are                subject. |

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

**3.       NOTES      PAYABLE**

|   | On                January 22, 2007, the company paid off the $150,000 note payable                outstanding at December 31, 2006, including interest for a total                of                $160,714. On February 7, 2007, the company also paid off the $100,000                bridge loan outstanding at December 31, 2006, including interest                for a                total of $101,897.  On June 28, 2007, the maturity date of the                note dated June 1, 2006 in the amount of $90,000  was extended                to December 31, 2007 at a per annum rate of                11.5%. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**4.       INCOME      TAXES**

|   | The                Company has incurred losses since inception, which have resulted                in net                operating loss carryforwards (NOLs). Since it is more likely than                not that                the Company will not realize the benefits from these NOLs, the Company                has                recorded a full valuation allowance against any future tax                benefits. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | The                tax effect of the temporary differences that give rise to the Company’s                net deferred tax assets at June 30, 2007 are as                follows:                                                                                                                                                                                                                                        |

|                                                                                                     |   | **2007** |       |
|----------------------------------------------------------------------------------------------------------|--------|----------|------------|
| Assets:                                                                                                  |   |     |       |
| Deferred                tax assets, noncurrent:                                                          |   |     |       |
| Net                operating loss carryforwards (NOL’s)                                            |   | $        | 2,475,510  |   |
|           Accrued                expenses              |   |     | 7,654      |   |
|           Accrued                compensation          |   |     | 134,833    |   |
|                                                                                                     |   |     |       |   |
| Liabilities:                                                                                             |   |     |       |   |
|      Deferred                tax liabilities, noncurrent:                       |   |     |       |   |
|           Depreciation                and amortization |   |     | (4,844     | ) |
| Subtotal                                                                                                 |   |     | 2,613,153  |   |
| Valuation                allowance                                                                       |   |     | (2,613,153 | ) |
| Net                deferred tax assets                                                                   |   | $        | -          |   |
|                                                                                                     |   |     |       |   |

|   | The                Company has recorded a valuation allowance to reflect the estimated                amount                of deferred tax assets that may not be realized due to the Company’s                inability to generate profits to utilize NOL’s. The net increase in the                valuation allowance is primarily related to increases in federal                and state                NOL carryovers. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|   | The                Company has approximately $6,188,775 in federal and state NOLs expiring                beginning in 2025 and 2012, respectively. Pursuant to Section 382                of the                Internal Revenue Code, in the event of an ownership change of more                than                50%, the ability of the Company to utilize NOL carry forwards may                be                limited.          |

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

**5.       SIGNIFICANT      RISKS AND UNCERTAINTIES**

|   | ***Concentration                of Cash Balance -*** The Company maintains its cash in bank                deposit accounts which, at times, may exceed federally insured limits.                The                Company has not experienced any losses in such accounts. The Company                believes it is not exposed to any significant credit risk on                cash.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   | **CONSULTING                AGREEMENTS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|   | *W.                Barry McDonald*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   | On                January 14, 2005, the Company entered into a consulting arrangement                with                W. Barry McDonald, under which, Mr. McDonald is to provide the company                with certain business development assistance in exchange for monthly                payments, success fees and a stock option to earn up to 5% of the                Company’s Common Stock on a fully diluted basis. Mr. McDonald was also                given a seat on the Company’s Board of Directors. Subsequent to the                adoption of the Company’s Stock Option Plan, in February 2007, our Board                of Directors agreed to grant W. Barry McDonald an option to purchase                one                share of HPD Common Stock (pre-merger common stock) for every five                hours                of consulting services that Mr. McDonald provides to HPD in 2007.                The                exercise price for each share of HPD Common Stock is $0.1354 per                share (on                a post-merger basis). Mr. McDonald agreed to work with our management                team                and provide 36 hours of consulting services per month, such consulting                services consisting of identifying and developing relationships with                companies whose diagnostic products are consistent with our strategy                (each, a “Target”) and objectives and assisting us with the implementation                of our business model. Such options vest at the end of each quarter                following the performance of the consulting services by Mr. McDonald.                Mr.                McDonald was granted 890,487 options, which represents 4% of the                Company                on a fully-diluted basis as of June 30, 2007 in connection with the                agreement noted above. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|   | Mr.                McDonald shall have the right to earn the remaining 1% of the Company’s                Common Stock on a fully-diluted basis as set forth above, upon the                consummation of a definitive agreement with a Target. The exercise                price                for such shares of HPD Common Stock is ** ** $0.1354 per                share (on a post-merger basis).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

**6.       RELATED      PARTY TRANSACTIONS**

|   | The                Company entered into its own two year lease agreement beginning January                2006 with annual rent in the amount of $75,350 per year. During March                2007, the Company entered into additional rental space for a one                year term                with annual rent in the amount of $17,600 per year. The Company will                continue to share rental space with the Gynetics, Inc., a business                run by                the Company’s current management. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

**7.       DEFINED      CONTRIBUTION RETIREMENT PLAN**

|   | The                Company maintains a 401(k) plan for its employees. Employees are                eligible                to participate in the plan immediately upon joining the Company.                Under the                terms of the plan, employees are entitled to contribute from 1% to                20% of                their total compensation, within the limitations established by the                Internal Revenue Code. The Company has agreed to make matching                contributions in the amount of 100% on the first 5% of compensation                deferred as an elective deferral allocated each payroll period. For                the                three and six months ended June 30, 2007, the Company’s contribution was                approximately $3,750 and $10,125, respectively, as compared to the                same                prior year periods of $2,667 and $6,667,                respectively. |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.       STOCK      BASED COMPENSATION**

|   | On                December 18, 2006, the HPD Board of Directors adopted the Healthcare                Providers Direct, Inc. Stock Option Plan (the “Plan”) which provides for                the grant of Incentive Stock Options and Nonqualified Stock Options.                On                December 27, 2006 our shareholders approved the Plan.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | The                Board of Directors has approved and adopted the 2007 Stock Incentive                Plan                by Unanimous Written Consent effective and dated June 26, 2007. Options                granted on March 28, 2007 to HPD employees are now exchanged for                options                granted to the same employees under the 2007 Healthcare Providers                Direct,                Inc. Incentive Stock Option Plan for equal number of options originally                granted in March and at the exercise price representing the closing                price                of the Corporations Common Stock on June 26, 2007. This transaction                was                accounted for as a modification.                                                                                                                                                                                                            |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | Key                employees, consultants and non-employee directors of the Company                are                eligible to receive awards under the Plan. Except to the extent set                forth                in any award agreement to the contrary, options granted under the                Plan                vest in three equal annual installments for non-employee directors                and in                four equal annual installments for all other option holders commencing                on                the first anniversary of the date of grant. Options are granted at                no less                than Fair Market Value.                                                                                                                                                                                                                                                                                               |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | The                Plan is administered by the Board of Directors which has full power                to                construe, administer and interpret the Plan, and to adopt such rules                and                regulations they deem desirable to administer the Plan. The determination                of the Board of Directors regarding disputes, questions, construction                and                interpretation of the Plan, is final, conclusive and binding. The                plan                permits the Board of Directors to delegate its authority to any person                it                deems appropriate.                                                                                                                                                                                                                                                                                                                   |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | There                are 6,402,672 shares of Common Stock reserved for issuance upon the                exercise of options. Options have a term of ten years. In the event                of a                termination of employment or service, options that are vested at                the time                of such termination generally remain exercisable for ninety days                in the                event of involuntary termination or termination due to retirement                or                disability, and for one year in the event of termination due to death.                Vested options are immediately canceled upon termination for “Cause”. All                unvested options are canceled immediately upon termination for any                reason.                Upon the date of a “change in control, all outstanding unvested options                become immediately vested and fully exercisable. |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | With                the initial grants of stock options during the six months ended June                30,                2007, the Company began recording compensation expense associated                with                stock options in accordance with SFAS No. 123(R).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|   | The                Company’s net loss for the three and six months ending June 30, 2007                includes $62,370 and $343,678, respectively, of compensation expense                related to stock option awards (“stock options”). As a result, basic and                diluted earnings per share for the three and six months ended June                30,                2007 were reduced by $0.001 and $0.008 per share,                respectively.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

|   | ***Stock                Options***Compensation                expense related to stock options granted is recognized ratably over                the                service vesting period for the entire option award. The total number                of                stock option awards expected to vest is adjusted by the estimated                forfeiture rate. The company is currently expecting no forfeitures.                The                estimated fair value of each stock option award was determined on                the date                of grant using the Black-Scholes option valuation model with the                following                weighted-average assumptions for the option                grants: |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | Assumptions:                        |   |   |   |
|--------|-------------------------------------|--------|--------|--------|
|   | Risk                Free Rate       | 4.92%  |   |   |
|   | Expected                Option Life | 5.0    | years  |   |
|   | Volatility                          | 71.00% |   |   |
|   | Dividend                Yield       | 0.0%   |   |   |

|   | The                computation of the expected option life is based on a weighted-average                calculation combining the average life of options that have already                been                exercised and post-vest cancellations with the estimated life of                the                remaining vested and unexercised options. The expected volatility                is based                on a peer public company. The risk-free interest rate is based on                the U.S.                Treasury yield curve over the expected term of the option. The Company                has                never paid cash dividends on its common stock and does not anticipate                paying cash dividends in the foreseeable future. Consequently, the                Company                uses an expected dividend yield of zero in the Black-Scholes option                valuation model. The Company’s estimated forfeiture rate is based on its                historical experience.      |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|   | The                Company’s determination of fair value is affected by the Company’s stock                price as well as a number of assumptions that require judgment. The                weighted-average fair value per share was approximately $0.370 and                $0.170                for the three and six months ended June 30, 2007, and no options                were                granted for the three and six months ended June 30, 2006. No options                were                exercised during the three and six months ended June 30, 2007 and                2006. As                of June 30, 2007, total unrecognized compensation cost related to                stock                options was approximately $538,126 and the related weighted-average                period                over which it is expected to be recognized is approximately 3.0 years.                The                maximum contractual term of the Company’s stock options is 10                years. |

----

**Healthcare      Providers Direct, Inc.**

**NOTES      TO THE CONDENSED FINANCIAL STATEMENTS**

**For        the three and six months ended June 30, 2007 and        2006**

----

|                                             |   |                                |      |   |                                |   |   | **Weighted                Average** |   |   |                                   |   |
|--------------------------------------------------|--------|-------------------------------------|-----------|--------|-------------------------------------|--------|--------|-------------------------------------|--------|--------|----------------------------------------|--------|
|                                             |   |                                |      |   | **Weighted                Average** |   |   | **Contractual                Term** |   |   | **Aggregate                Intrinsic** |   |
| Summary                of activity:              |   | **Number                of Shares** |      |   | **Exercise                Price**   |   |   | **(in                years)**       |   |   | **Value**                              |   |
| Outstanding                at December 31, 2006: |   |                                | -         |   |                                | $      | -      |                                |   |   | -                                      |   |   | $ | - |   |
| Granted                                          |   |                                | 2,597,209 |   |                                | $      | 0.27   |                                |   |   | 10                                     |   |   |   | 443,749 |   |
| Exercised                                        |   |                                | -         |   |                                | $      | -      |                                |   |   | -                                      |   |   |   | - |   |
| Cancelled                                        |   |                                | -         |   |                                | $      | -      |                                |   |   | -                                      |   |   |   | - |   |
| Outstanding                at June 30, 2007:     |   |                                | 2,597,209 |   |                                | $      | 0.27   |                                |   |   | 10                                     |   |   | $ | 443,749 |   |
|                                             |   |                                |      |   |                                |   |   |                                |   |   |                                   |   |   |   |   |   |
| Vested                and Expected to Vest:      |   |                                | 2,597,209 |   |                                |   |   |                                |   |   |                                   |   |   |   |   |   |
| Exercisable:                                     |   |                                | 1,161,269 |   |                                |   |   |                                |   |   |                                   |   |   |   |   |   |
|                                             |   |                                |      |   |                                |   |   |                                |   |   |                                   |   |   |   |   |   |
| Available                for future grants:      |   |                                | 3,804,863 |   |                                |   |   |                                |   |   |                                   |   |   |   |   |   |
|                                             |   |                                |      |   |                                |   |   |                                |   |   |                                   |   |   |   |   |   |

|                                        |                         |   |                                   |   |      | **Weighted                Average**      |   |   |                                |   |   |                                   |   |   | **Weighted                Average**    |   |
|---------------------------------------------|------------------------------|--------|----------------------------------------|--------|-----------|------------------------------------------|--------|--------|-------------------------------------|--------|--------|----------------------------------------|--------|--------|----------------------------------------|--------|
|                                        |                         |   |                                   |   |      | **Remaining                Contractual** |   |   | **Weighted                Average** |   |   |                                   |   |   | **Exercise                Prices of**  |   |
| **Range                of Exercise Prices** |                         |   | **Options                Outstanding** |   |      | **Life**                                 |   |   | **Exercise                Price**   |   |   | **Options                Exercisable** |   |   | **Options                Exercisable** |   |
| $                                           | 0.13                to $0.14 |   |                                   |   | 1,847,209 |                                     |   |   | 9.6                                 |   |   | $                                      | 0.1354 |   |                                   |   | 1,111,269 |   |   | $ | 0.1354 |   |
| $                                           | 0.60                         |   |                                   |   | 750,000   |                                     |   |   | 10.0                                |   |   | $                                      | 0.60   |   |                                   |   | 50,000 |   |   | $ | 0.60 |   |
|                                        |                         |   |                                   |   | 2,597,209 |                                     |   |   |                                |   |   |                                   |   |   |                                   |   | 1,161,269 |   |   | $ | 0.1554 |   |

**9.      SUBSEQUENT EVENTS**

|   | On                July 16, 2007, the Company issued a promissory note in the amount                of                $50,000 to an officer of the Company. This interest free note matures                on                August 31, 2007 and is secured by the assets of the Company. During                the third quarter of 2007, the Company received $1,250,000 in proceeds                through a private placement offering of 9% Senior Secured Convertible                Debentures (the “9% Debentures”). The 9% debenture is convertible into                common stock at a conversion price of $0.25 and matures in three                years. In                connection with the private placement, the Company also issued five                year                warrants to purchase up to 5,000,000 shares of common stock with                an                exercise price of $0.50 per shares. The                proceeds from the private placement have been allocated on a relative                fair                value basis between the debt and the warrants. This allocation resulted                in                notes payable of $300,656, discount on the notes payable and additional                paid in capital of $300,656, and $949,344 paid in capital for the                warrant                issuance.  In addition, since the effective conversion price of                the 9% Debentures was less than the market value of the Common Stock                on                the date of issuance, a beneficial conversion feature equal to the                remaining amount of the 9% Debentures was recorded as a further discount                to notes payable and an increase to additional paid in                capital.  The resulting discount on the 9% Debentures, which is                equal to the face amount of the notes, will be amortized to interest                expense over the term of the notes. The                Company capitalized $251,544 as deferred financing fees for direct                costs                of the private placement. The deferred financing fees will be amortized                over the term of the debt. Included in deferred financing costs are                100,000 in warrants issued to the placement agent for services provided                in                connection with the private placement. These warrants had a fair                value on                the date of issuance of $81,544. The                Company is obligated to file a registration statement registering                the                resale of the shares of the Common Stock issuable upon conversion                of the                Debentures, and the Common Stock issuable upon exercise of the Warrants,                and the shares of common stock issuable as payment of interest on                the                Debenture. If the registration statement is not filed within 30 days                from                the final closing, or declared effective within 90 days thereafter                (150                days if the registration statement receives a review by the SEC),                the                Company is obligated to pay the investors certain fees in the amount                of                1.5% of the total purchase price of the Debentures, per month, and                the                obligations may be deemed to be in default.  |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

** Item      2. Management’s Discussion and Analysis or Plan of      Operations**

**Financial      Overview**

**Current      trends and outlook**

----

**Revenue      Sources**

**Critical      Accounting Estimates**

*Allowance      for Doubtful Accounts*

* *

*Impairment      of Long Lived Assets*

*Valuation      allowance for Income Taxes*

*Accounting for Income Taxes*

----

**Results      of Operations**

**Three      Months Ended June 30, 2007 and 2006**

**Revenues**

**Cost      of Sales**

**Gross      Margin**

**Expenses**

*General      and Administrative*

----

*Research      and Development*

*Sales      and Marketing*

*Operating      Loss*

*Other      income (Expense)*

*Net      Loss*

**Six      Months Ended June 30, 2007 and 2006**

**Revenues**

**Cost      of Sales**

**Gross      Margin**

**Expenses**

*Merger      Related*

*General      and Administrative*

----

*Research      and Development*

*Sales      and Marketing*

*Operating      Loss*

*Other      income (Expense)*

*Net      Loss*

*Seasonality*

----

**Liquidity and**
**Capital      Resources**

*Future      Liquidity and Capital Needs*

----

| ·   | The                magnitude and scope of our research and development programs and                our                ability to establish, enforce and maintain strategic                arrangement |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | for                research, development, clinical testing, manufacturing and                marketing; |
|--------|---------------------------------------------------------------------------------------------------------|

| ·   | our                progress with preclinical development and clinical                trials; |
|--------------------|----------------------------------------------------------------------------------------------|

| ·   | the                time and costs involved in obtaining regulatory                approvals; |
|--------------------|----------------------------------------------------------------------------------------------|

| ·   | the                costs involved in preparing, filing, prosecuting, maintaining, defending                and enforcing patents; and claims;                and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | the                number and type of product candidates that we                pursue. |
|--------------------|-----------------------------------------------------------------------------------------|

|                        |   | **2007** |   | **2008** |
|-----------------------------|--------|----------|--------|----------|
| Office                Lease | $      | 46,475   | $      | 15,081   |

**2007**

**2008**

**Off        Balance Sheet Arrangements**

**ITEM      3.**
**CONTROLS      AND      PROCEDURES**

----

**Part      II.**
**OTHER      INFORMATION**

**Item      1.**
**Legal      Proceedings**

**Item      2.**
**Unregistered      Sales      of Equity Securities and Use of Proceeds**

**Item      3.**
**Defaults      Upon      Senior Securities**

**Item      4.**
**Submission      of      Matters to a Vote of Security Holders**

**Item      5.**
**Other      Information**

**Item      6.**
**Exhibits**

| (a)   | Exhibits |
|-----------------|----------|

| **Exhibit                Number** |   | **Description                of Exhibit**                                                                                                                                                                    |
|-----------------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.1                              |   | Certification                of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a),                promulgated under the Securities and Exchange Act of 1937, asamended                  |
| 31.2                              |   | Certification                of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d                14(a),                promulgated under the Securities and Exchange Act of 1934, asamended   |
| 32.1                              |   | Certification                pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section                906 of                the Sarbanes-Oxley Act of 2002 (Chief Executive                Officer) |
| 32.2                              |   | Certification                pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section                906 of                the Sarbanes-Oxley Act of 2002 (Chief Executive                Officer) |

----

**SIGNATURES**

| In                accordance with the requirements of the Exchange Act, the registrant                caused this report to be signed on its behalf by the undersigned,                thereunto duly authorized. |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                              |   |   |   |   |
|                                                                                                                                                                                                              |   |   |   |   |
|                                                                                                                                                                                                              |   | Healthcare                Providers Direct, Inc. |
|                                                                                                                                                                                                              |   |   |   |   |
|                                                                                                                                                                                                              |   |   |   |   |
| Date:  August                14, 2007                                                                                                                                                                   |   | By:  /s/                Norman Proulx |   |   |
|                                                                                                                                                                                                              |   |   |   |   |
|                                                                                                                                                                                                              |   | Norman                Proulx |   |   |
|                                                                                                                                                                                                              |   | Chief                Executive Officer (Principal Executive Officer) and Chief Financial                Officer (Principal Financial |
|                                                                                                                                                                                                              |   | and                Accounting Officer) |
|                                                                                                                                                                                                              |   |   |
|                                                                                                                                                                                                              |   |   |